Top Neuroscience Partnering Opportunities: Seeking To Alter Treatment Paradigms
This article was originally published in The Pink Sheet Daily
Neuroscience track at the Therapeutic Area Partnerships conferencewill feature novel candidates for Alzheimer’s, depression, traumatic brain injury, Fragile X syndrome and post-herpetic neuralgia.
You may also be interested in...
The PBT2 compound boosts executive function in first Phase II trial, but fails all other efficacy endpoints; however, past regulatory experience suggests that with few treatment options, one endpoint can do the trick in hard-to-treat Huntington’s disease.
Leading Alzheimer’s experts discuss the status of new therapeutic approaches based on the pathophysiology of related diseases, new gene discoveries from GWAS, the inflammatory cascade and environmental epigenetics. Surprisingly, there is still untapped promise in a-beta and tau.
Targacept says it will continue to develop its schizophrenia drug, even though AstraZeneca has opted not to move forward.